secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001193125-21-324463
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO closes $370M upfront eye care collaboration with AbbVie for RGX-314 gene therapy
--------------------------------------------------------------------------------

- Upfront payment of $370M; potential for up to $1.38B in development, regulatory, and commercial milestones.
- REGENXBIO and AbbVie to share equally in US profits; AbbVie to pay tiered royalties on ex-US net sales.
- REGENXBIO responsible for ongoing trials; AbbVie leads global clinical development and commercialization.
- REGENXBIO to lead manufacturing for clinical and US commercial supply; AbbVie for ex-US commercial supply.
- Agreement covers RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312521324463/0001193125-21-324463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312521324463/d257796d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-324463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer